First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. (Q30657829)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

D W Miles

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

V Diéras

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

A-A Duenne

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Yi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

25 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

2773-2780

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23894038%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Avastin saga reveals debate over clinical trial endpoints.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Targeting triple-negative breast cancer: optimising therapeutic outcomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT276

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30657829&oldid=1984595273"